NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

Management of NAFLD: a review

As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH.
Anti-inflammatory, anti-fibrotic agents and metabolism modulators...
Read MoreManagement of NAFLD: a review

Is Europe ready to meet the challenge of fatty liver disease?

NAFLD is closely associated with obesity, metabolic syndrome, and diabetes. NAFLD can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures. NAFLD preparedness means having adequate policies and civil society...
Read MoreIs Europe ready to meet the challenge of fatty liver disease?

Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

Prof. Kenneth Cusi

Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.

Read MoreManagement of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

Changing trends of liver transplantation and mortality from NAFLD

This review by A. Majumdar (Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, and University of Sydney, Australia) and E. Tsochatzis (UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, and Sheila Sherlock Liver Centre, Royal Free Hospital, London, UK) outlines the current epidemiology, natural history...
Read MoreChanging trends of liver transplantation and mortality from NAFLD

Prevalence of steatosis and fibrosis in young adults in the UK

The study by KWM Abeysekera et al. (Population Health Sciences, Bristol Medical School, University of Bristol, and University Hospitals Bristol NHS Foundation Trust, Bristol, UK) is the first to determine the prevalence of NAFLD in young adults with use of transient electrography, in an age group in which NAFLD burden is poorly characterized...
Read MorePrevalence of steatosis and fibrosis in young adults in the UK

NAFLD patients: cost effectiveness of different strategies for detecting cirrhosis

Several strategies are available for detecting cirrhosis in patients with NAFLD, but their cost effectiveness is not clear. E. Vilar-Gomez et al. (Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA) developed a decision model to...
Read MoreNAFLD patients: cost effectiveness of different strategies for detecting cirrhosis

Randomized Control Trial: Fecal microbiota transplantation in NAFLD patients

The gut microbiome plays a role in metabolism and maintaining gut barrier integrity, and fecal microbiota transplantation can be used to alter the gut microbiome. The authors hypothesized that a fecal microbiota transplantation from a thin and healthy donor given to patients with NAFLD...
Read MoreRandomized Control Trial: Fecal microbiota transplantation in NAFLD patients

From NASH to hepatocellular carcinoma

End-stage NAFLD with liver cancer has an abysmal prognosis and effective medical therapies are lacking, therefore a better understanding of the disease mechanisms will ultimately help to improve patients’ care. The pathogenesis of NAFLD and transition to HCC is multifactorial, yet inflammation is considered a key element...
Read MoreFrom NASH to hepatocellular carcinoma